{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:43:46Z","timestamp":1787064226353,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["8137311"],"award-info":[{"award-number":["8137311"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100017959","name":"Hebei Provincial Health Commission","doi-asserted-by":"crossref","award":["20190105"],"award-info":[{"award-number":["20190105"]}],"id":[{"id":"10.13039\/100017959","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-83447-8","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T15:40:02Z","timestamp":1735573202000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["HDAC3 inhibitors induce drug resistance by promoting IL-17\u00a0A production by T cells"],"prefix":"10.1038","volume":"14","author":[{"given":"Hao","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anqi","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aihong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WenTing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanhui","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,30]]},"reference":[{"key":"83447_CR1","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1073\/pnas.95.6.2795","volume":"95","author":"S Emiliani","year":"1998","unstructured":"Emiliani, S., Fischle, W., Van Lint, C., Al-Abed, Y. & Verdin, E. Characterization of a human RPD3 ortholog, HDAC3. Proc. Natl. Acad. Sci. USA 95, 2795\u20132800. https:\/\/doi.org\/10.1073\/pnas.95.6.2795 (1998).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"83447_CR2","doi-asserted-by":"publisher","first-page":"eadd3243","DOI":"10.1126\/sciadv.add3243","volume":"9","author":"LJ Eichner","year":"2023","unstructured":"Eichner, L. J. et al. HDAC3 is critical in tumor development and therapeutic resistance in Kras-mutant non-small cell lung cancer. Sci. Adv. 9, eadd3243. https:\/\/doi.org\/10.1126\/sciadv.add3243 (2023).","journal-title":"Sci. Adv."},{"key":"83447_CR3","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/s43018-022-00375-0","volume":"3","author":"KK Tsai","year":"2022","unstructured":"Tsai, K. K. et al. Screening of organoids derived from patients with breast cancer implicates the repressor NCOR2 in cytotoxic stress response and antitumor immunity. Nat. Cancer 3, 734\u2013752. https:\/\/doi.org\/10.1038\/s43018-022-00375-0 (2022).","journal-title":"Nat. Cancer"},{"key":"83447_CR4","doi-asserted-by":"publisher","first-page":"3676","DOI":"10.1158\/0008-5472.can-18-3767","volume":"79","author":"H Ji","year":"2019","unstructured":"Ji, H. et al. HDAC3 deficiency promotes liver cancer through a defect in H3K9ac\/H3K9me3 transition. Cancer Res. 79, 3676\u20133688. https:\/\/doi.org\/10.1158\/0008-5472.can-18-3767 (2019).","journal-title":"Cancer Res."},{"key":"83447_CR5","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.tips.2017.11.008","volume":"39","author":"I Vancurova","year":"2018","unstructured":"Vancurova, I., Uddin, M. M., Zou, Y. & Vancura, A. Combination therapies targeting HDAC and IKK in solid tumors. Trends Pharmacol. Sci. 39, 295\u2013306. https:\/\/doi.org\/10.1016\/j.tips.2017.11.008 (2018).","journal-title":"Trends Pharmacol. Sci."},{"key":"83447_CR6","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/s1470-2045(19)30164-0","volume":"20","author":"Z Jiang","year":"2019","unstructured":"Jiang, Z. et al. Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 20, 806\u2013815. https:\/\/doi.org\/10.1016\/s1470-2045(19)30164-0 (2019).","journal-title":"Lancet Oncol."},{"key":"83447_CR7","doi-asserted-by":"publisher","first-page":"112171","DOI":"10.1016\/j.ejmech.2020.112171","volume":"192","author":"R Sarkar","year":"2020","unstructured":"Sarkar, R., Banerjee, S., Amin, S. A., Adhikari, N. & Jha, T. Histone deacetylase 3 (HDAC3) inhibitors as anticancer agents: A review. Eur. J. Med. Chem. 192, 112171. https:\/\/doi.org\/10.1016\/j.ejmech.2020.112171 (2020).","journal-title":"Eur. J. Med. Chem."},{"key":"83447_CR8","doi-asserted-by":"publisher","first-page":"114118","DOI":"10.1016\/j.bcp.2020.114118","volume":"180","author":"H Liang","year":"2020","unstructured":"Liang, H. et al. RGFP966, a histone deacetylase 3 inhibitor, promotes glioma stem cell differentiation by blocking TGF-beta signaling via SMAD7. Biochem. Pharmacol. 180, 114118. https:\/\/doi.org\/10.1016\/j.bcp.2020.114118 (2020).","journal-title":"Biochem. Pharmacol."},{"key":"83447_CR9","doi-asserted-by":"publisher","first-page":"12033","DOI":"10.1021\/acs.jmedchem.3c00614","volume":"66","author":"S Pulya","year":"2023","unstructured":"Pulya, S. et al. Selective HDAC3 inhibitors with potent in vivo antitumor efficacy against triple-negative breast cancer. J. Med. Chem. 66, 12033\u201312058. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c00614 (2023).","journal-title":"J. Med. Chem."},{"key":"83447_CR10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13046-020-1536-x","volume":"39","author":"H Wang","year":"2020","unstructured":"Wang, H. et al. Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1\/c-Jun\/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells. J. Exp. Clin. Cancer Res. 39, 29. https:\/\/doi.org\/10.1186\/s13046-020-1536-x (2020).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"83447_CR11","doi-asserted-by":"publisher","first-page":"3854","DOI":"10.1128\/MCB.00706-15","volume":"35","author":"KR Stengel","year":"2015","unstructured":"Stengel, K. R. et al. Histone deacetylase 3 is required for efficient T cell development. Mol. Cell. Biol. 35, 3854\u20133865. https:\/\/doi.org\/10.1128\/MCB.00706-15 (2015).","journal-title":"Mol. Cell. Biol."},{"key":"83447_CR12","doi-asserted-by":"publisher","first-page":"541","DOI":"10.4049\/jimmunol.1502529","volume":"197","author":"RL Philips","year":"2016","unstructured":"Philips, R. L. et al. HDAC3 is required for the downregulation of RORgammat during thymocyte positive selection. J. Immunol. 197, 541\u2013554. https:\/\/doi.org\/10.4049\/jimmunol.1502529 (2016).","journal-title":"J. Immunol."},{"key":"83447_CR13","doi-asserted-by":"publisher","first-page":"e43821","DOI":"10.7554\/elife.43821","volume":"8","author":"RL Philips","year":"2019","unstructured":"Philips, R. L. et al. HDAC3 restrains CD8-lineage genes to maintain a bi-potential state in CD4(+)CD8(+) thymocytes for CD4-lineage commitment. Elife 8, e43821. https:\/\/doi.org\/10.7554\/elife.43821 (2019).","journal-title":"Elife"},{"key":"83447_CR14","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1158\/2326-6066.cir-22-0317","volume":"11","author":"L Li","year":"2023","unstructured":"Li, L. et al. HDAC3 inhibition promotes antitumor immunity by enhancing CXCL10-mediated chemotaxis and recruiting of immune cells. Cancer Immunol. Res. 11, 657\u2013673. https:\/\/doi.org\/10.1158\/2326-6066.cir-22-0317 (2023).","journal-title":"Cancer Immunol. Res."},{"key":"83447_CR15","doi-asserted-by":"publisher","first-page":"e68915","DOI":"10.1371\/journal.pone.0068915","volume":"8","author":"CE Wells","year":"2013","unstructured":"Wells, C. E. et al. Inhibition of histone deacetylase 3 causes replication stress in cutaneous T cell lymphoma. PLoS One 8, e68915. https:\/\/doi.org\/10.1371\/journal.pone.0068915 (2013).","journal-title":"PLoS One"},{"key":"83447_CR16","doi-asserted-by":"publisher","first-page":"102971","DOI":"10.1016\/j.jbc.2023.102971","volume":"299","author":"H Zhang","year":"2023","unstructured":"Zhang, H. et al. Acetylation stabilizes the signaling protein WISP2 by preventing its degradation to suppress the progression of acute myeloid leukemia. J. Biol. Chem. 299, 102971. https:\/\/doi.org\/10.1016\/j.jbc.2023.102971 (2023).","journal-title":"J. Biol. Chem."},{"key":"83447_CR17","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2147\/DDDT.S234871","volume":"14","author":"X Yu","year":"2020","unstructured":"Yu, X. et al. RGFP966 suppresses tumor growth and migration through inhibition of EGFR expression in hepatocellular carcinoma cells in vitro. Drug Des. Dev. Ther. 14, 121\u2013128. https:\/\/doi.org\/10.2147\/DDDT.S234871 (2020).","journal-title":"Drug Des. Dev. Ther."},{"key":"83447_CR18","doi-asserted-by":"publisher","first-page":"e8478","DOI":"10.15252\/emmm.201708478","volume":"10","author":"Y Yan","year":"2018","unstructured":"Yan, Y. et al. Dual inhibition of AKT-mTOR and AR signaling by targeting HDAC3 in PTEN- or SPOP-mutated prostate cancer. EMBO Mol. Med. 10, e8478. https:\/\/doi.org\/10.15252\/emmm.201708478 (2018).","journal-title":"EMBO Mol. Med."},{"key":"83447_CR19","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/ni.2035","volume":"12","author":"EJ Wherry","year":"2011","unstructured":"Wherry, E. J. T cell exhaustion. Nat. Immunol. 12, 492\u2013499. https:\/\/doi.org\/10.1038\/ni.2035 (2011).","journal-title":"Nat. Immunol."},{"key":"83447_CR20","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","volume":"19","author":"A Chow","year":"2022","unstructured":"Chow, A., Perica, K., Klebanoff, C. A. & Wolchok, J. D. Clinical implications of T cell exhaustion for cancer immunotherapy. Nat. Rev. Clin. Oncol. 19, 775\u2013790. https:\/\/doi.org\/10.1038\/s41571-022-00689-z (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"83447_CR21","doi-asserted-by":"publisher","first-page":"669474","DOI":"10.3389\/fimmu.2021.669474","volume":"12","author":"A Basu","year":"2021","unstructured":"Basu, A. et al. Differentiation and regulation of T(H) cells: a balancing act for cancer immunotherapy. Front. Immunol. 12, 669474. https:\/\/doi.org\/10.3389\/fimmu.2021.669474 (2021).","journal-title":"Front. Immunol."},{"key":"83447_CR22","doi-asserted-by":"publisher","first-page":"761448","DOI":"10.3389\/fimmu.2021.761448","volume":"12","author":"H Jiang","year":"2021","unstructured":"Jiang, H., Fu, D., Bidgoli, A. & Paczesny, S. T. Cell subsets in graft versus host disease and graft versus tumor. Front. Immunol. 12, 761448. https:\/\/doi.org\/10.3389\/fimmu.2021.761448 (2021).","journal-title":"Front. Immunol."},{"key":"83447_CR23","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.cmet.2023.02.013","volume":"35","author":"LC Nava","year":"2023","unstructured":"Nava, L. C. et al. Linoleic acid potentiates CD8(+) T cell metabolic fitness and antitumor immunity. Cell Metab. 35, 633\u2013650. https:\/\/doi.org\/10.1016\/j.cmet.2023.02.013 (2023).","journal-title":"Cell Metab."},{"key":"83447_CR24","doi-asserted-by":"publisher","first-page":"e20190354","DOI":"10.1084\/jem.20190354","volume":"217","author":"Y Zhang","year":"2020","unstructured":"Zhang, Y. et al. Interleukin-17-induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer. J. Exp. Med. 217, e20190354. https:\/\/doi.org\/10.1084\/jem.20190354 (2020).","journal-title":"J. Exp. Med."},{"key":"83447_CR25","doi-asserted-by":"publisher","first-page":"699478","DOI":"10.3389\/fimmu.2021.699478","volume":"12","author":"Z Zhang","year":"2021","unstructured":"Zhang, Z. et al. \u03b3\u03b4T Cell-IL17A-neutrophil axis drives immunosuppression and confers breast cancer resistance to high-dose anti-VEGFR2 therapy. Front. Immunol. 12, 699478. https:\/\/doi.org\/10.3389\/fimmu.2021.699478 (2021).","journal-title":"Front. Immunol."},{"key":"83447_CR26","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1289\/ehp.1510194","volume":"124","author":"CF Vogel","year":"2016","unstructured":"Vogel, C. F. et al. Transgenic overexpression of aryl hydrocarbon receptor repressor (AhRR) and AhR-mediated induction of CYP1A1, cytokines, and acute toxicity. Environ. Health Perspect. 124, 1071\u20131083. https:\/\/doi.org\/10.1289\/ehp.1510194 (2016).","journal-title":"Environ. Health Perspect."},{"key":"83447_CR27","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1158\/0008-5472.can-15-1439","volume":"76","author":"S Koyama","year":"2016","unstructured":"Koyama, S. et al. STK11\/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor microenvironment. Cancer Res. 76, 999\u20131008. https:\/\/doi.org\/10.1158\/0008-5472.can-15-1439 (2016).","journal-title":"Cancer Res."},{"key":"83447_CR28","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1016\/j.cmet.2023.09.004","volume":"35","author":"Y Zhao","year":"2023","unstructured":"Zhao, Y. et al. Neutrophils resist ferroptosis and promote breast cancer metastasis through aconitate decarboxylase 1. Cell Metab. 35, 1688\u20131703. https:\/\/doi.org\/10.1016\/j.cmet.2023.09.004 (2023).","journal-title":"Cell Metab."},{"key":"83447_CR29","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1136\/gutjnl-2016-313075","volume":"66","author":"TT Wang","year":"2017","unstructured":"Wang, T. T. et al. Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway. Gut 66, 1900\u20131911. https:\/\/doi.org\/10.1136\/gutjnl-2016-313075 (2017).","journal-title":"Gut"},{"key":"83447_CR30","doi-asserted-by":"publisher","first-page":"672","DOI":"10.3389\/fcell.2020.00672","volume":"8","author":"Q Lei","year":"2020","unstructured":"Lei, Q., Wang, D., Sun, K., Wang, L. & Zhang, Y. Resistance mechanisms of anti-PD1\/PDL1 therapy in solid tumors. Front. Cell Dev. Biol. 8, 672. https:\/\/doi.org\/10.3389\/fcell.2020.00672 (2020).","journal-title":"Front. Cell Dev. Biol."},{"key":"83447_CR31","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41586-019-1325-x","volume":"571","author":"O Khan","year":"2019","unstructured":"Khan, O. et al. TOX transcriptionally and epigenetically programs CD8(+) T cell exhaustion. Nature 571, 211\u2013218. https:\/\/doi.org\/10.1038\/s41586-019-1325-x (2019).","journal-title":"Nature"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83447-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83447-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83447-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T10:39:39Z","timestamp":1735641579000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83447-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,30]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["83447"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-83447-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4885835\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,30]]},"assertion":[{"value":"9 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"We confirmed that all experiments in this study were performed in accordance with the relevant guidelines and regulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Accordance"}},{"value":"All the procedure of the study is followed by the ARRIVE guidelines.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Arrive"}}],"article-number":"31937"}}